ArticleEndoscopy international open2025
Single-center, prospective study evaluating safety and efficacy of a new endoscopic hemostat system in non-variceal upper gastrointestinal bleeding.
Article in Endoscopy international open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and study aims: Endoscopic spray therapy has been shown to be effective and safe in managing upper gastrointestinal bleeding (UGIB). We aimed to evaluate safety and efficacy of the novel powder-based Resolv Endoscopic Hemostat System in managing UGIB. Patients and methods: This was a single-center, prospective, single-arm study conducted from July 2022 to February 2023. It aimed to evaluate safety and efficacy of a novel plant-based polysaccharide, the Resolv Endoscopic Hemostat System, in achieving hemostasis in adult patients diagnosed with non-variceal upper gastrointestinal bleeding (UGIB) (Forest 1b/oozing bleeding). Participants in this study underwent endoscopy and received monotherapy treatment using the Resolv Endoscopic Hemostat System. Outcomes of interest were adverse events (AEs) related to the device within 72 hours and 30 days, immediate hemostasis, and rebleeding rates within 72 hours of the index procedure. Results: A total of 59 patients (71.2% men) with mean age of 55.3 ± 14.2 years were included in the study. Causes of bleeding included post-polypectomy (n = 35, 59.3%), gastric ulcers (n = 13, 22%), malignant tumor (n = 4, 6.8%), post-biopsy-related needing hemostasis (n = 3, 5.1%), congestive gastropathy (n = 2, 3.4%), duodenal ulcer (n = 1, 1.7%), and portal hypertensive duodenopathy-related (n = 1, 1.7%). Resolv achieved a 100% success rate for immediate hemostasis with a 72-hour rebleeding rate of 5.1%. There were no AEs related to the device or mortality. Conclusions: Resolv Endoscopic Hemostat System is a safe and effective device for achieving immediate hemostasis in patients with non-variceal upper gastrointestinal bleeding. Future studies are required to examine its widespread adoption and applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.